Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Remission After Potassium Iodide Therapy in Patients With Graves’ Hyperthyroidism Exhibiting Thionamide-Associated Side Effects
source: The Journal of Clinical Endocrinology and Metabolism
year: 2014
authors: Okamura K, Sato K, Fujikawa M, Bandai S, Ikenoue H, Kitazono T
summary/abstract:Context:
Thionamides have various side effects.
Objective:
The effectiveness of potassium iodide (KI) was evaluated in hyperthyroid patients who experienced side effects to thionamides.
Design and Setting:
An observational study was conducted at an academic medical center.
Patients:
Among 1388 patients with Graves’ hyperthyroidism treated with thionamides, 204 (14.7%) exhibited side effects, and 44 were treated with KI and followed for 17.6 (median; range, 8.6-28.4) years.
Main Outcome Measures:
The primary endpoint was the initial response to KI, and the secondary endpoint was the long-term prognosis.
Results:
The conditions of 29 (65.9%) of the 44 patients were well controlled with KI alone (10-400 mg/d) (A group), and 17 (38.6%) patients went into remission after 7.4 (1.9-23.0) years. The conditions of 15 (34.1%) patients were not controlled with KI alone (B group), even at a high dose (100-750 mg/d), but seven patients (15.9%) were controlled with a combination of KI and low-dose thionamides, resulting in remission after 7.2 (2.8-10.8) years. The initial parameters did not predict the response to KI or long-term prognosis. However, remission occurred in 70.8% of the patients treated with less than 200 mg of KI, compared with 35.0% of the patients who required 200 mg or more of KI (P < .05).
Conclusions:
Among hyperthyroid patients with thionamide-associated side effects, KI therapy was effective in two-thirds of cases, and about 40% of the patients experienced remission after KI therapy alone. The chance of remission was small among the patients refractory to KI.
DOI: 10.1210/jc.2013-4466
read more full text
myBinderRelated Content
-
Successful Re-Administration of Low-Dose of Methimazole (MMI) in Graves’ Disease Patients who Experienced Alle...Objective: When patients with Graves' d...
-
Management of Endocrine Disease: Arguments for the Prolonged Use of Antithyroid Drugs in Children With Graves’...Graves' disease is an autoimmune disorde...
-
Radioiodine Therapy Versus Antithyroid Medications for Graves’ DiseaseBackground: Graves' disease is the most...
-
Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves’ Disease RelapseBackground: Thionamides are associated ...
-
Most Graves’ Disease Treated With Antithyroid DrugsAdults with Graves’ disease are more l...
-
Is My Thyroid Condition to Blame for My Hair Loss?Question: Could my thyroid condition be ...
-
Optimal Iodine Supplementation During Antithyroid Drug Therapy for Graves’ Disease Is Associated With Lower Re...Objective: A relationship between iodin...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google